You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

Article metrics

Article menu

Download PDFPDF

Letter
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

 

Online download statistics by month:

Online download statistics by month: January 2022 to March 2024

AbstractFullPdf
Jan 2022025583
Feb 2022011241
Mar 2022010033
Apr 20220739
May 202206921
Jun 202206812
Jul 20220635
Aug 20220756
Sep 202207817
Oct 202207921
Nov 202205511
Dec 20220424
Jan 20230294
Feb 20230455
Mar 20230207
Apr 20230154
May 20230188
Jun 20230209
Jul 20230137
Aug 20230145
Sep 20230114
Oct 2023094
Nov 20230113
Dec 20230195
Jan 202402113
Feb 202401310
Mar 202402553
Total01352404